Edition:
India

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

1.14USD
7 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.14
Open
$1.21
Day's High
$1.21
Day's Low
$1.13
Volume
16,298
Avg. Vol
49,835
52-wk High
$5.53
52-wk Low
$0.83

Latest Key Developments (Source: Significant Developments)

Avenue Therapeutics Reports Q2 Loss Per Share $0.45
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.45.AS OF JUNE 30, 2018, AVENUE'S CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $8.9 MILLION.  Full Article

Mustang Bio Q2 Loss Per Share $0.19
Tuesday, 14 Aug 2018 

Mustang Bio Inc ::MUSTANG BIO REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.19.ON TRACK TO FILE AN IND IN Q4 FOR CD123 CAR T, MB-102.  Full Article

Mustang Bio Expects To Apply For Permission For Human Trials Of MB-102 Drug In Q4
Thursday, 19 Jul 2018 

July 19 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO COMPLETES PRE-IND MEETING WITH FDA FOR MB-102 (CD123 CAR T).MUSTANG BIO INC - WILL CONTINUE ITS EFFORTS ON ITS IND FILING TO FDA FOR MB-102..MUSTANG BIO INC - EXPECT TO SUBMIT AN IND FILING FOR MB-102 IN Q4 AS PLANNED.MUSTANG BIO - ANTICIPATE MANUFACTURING FACILITY WILL BE READY TO PROCESS PATIENT CELLS IN NEXT FEW MONTHS.  Full Article

Fortress Biotech Files For Mixed Shelf Of Up To $50 Mln - SEC Filing
Saturday, 7 Jul 2018 

July 6 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH INC FILES FOR MIXED SHELF OF UP TO $50 MILLION - SEC FILING.  Full Article

Fortress Biotech Says US FDA Grants Fast Track Designation to Cyprium's CUTX-101
Monday, 2 Jul 2018 

July 2 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH ANNOUNCES CYPRIUM THERAPEUTICS’ CUTX-101 (COPPER HISTIDINATE) GRANTED FDA FAST TRACK DESIGNATION FOR TREATMENT OF CLASSIC MENKES DISEASE.  Full Article

Avenue Therapeutics Reports Positive Topline Phase 3 Data For Intravenous Tramadol In The Management Of Postoperative Pain
Monday, 21 May 2018 

May 21 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FOR INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - INITIATION OF SECOND PIVOTAL PHASE 3 TRIAL PLANNED FOR Q3 OF 2018.AVENUE THERAPEUTICS INC - IV TRAMADOL WAS WELL-TOLERATED WITH NO REPORTS OF DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL.AVENUE THERAPEUTICS INC - IV TRAMADOL 25 MG TREATMENT ARM GENERALLY DISPLAYED INTERMEDIATE RESULTS THAT FELL BETWEEN 50 MG AND PLACEBO ARMS.AVENUE THERAPEUTICS - ANTICIPATE FILING NDA FOR IV TRAMADOL WITH U.S. FDA IN LATE 2019.  Full Article

Mustang Bio Reports Q4 Financial Results
Friday, 30 Mar 2018 

March 29 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.FORTRESS BIOTECH - ‍AS OF DEC 31, 2017, MUSTANG'S CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH TOTALED $61.5 MILLION.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL.MUSTANG BIO - INVESTIGATORS FOUND INFUSIONS OF MB-102 ARE SAFE AND WELL TOLERATED.MUSTANG BIO - CAR T THERAPY IS SAFE, WELL TOLERATED.  Full Article

Mustang Bio reports Q3 loss per share of $0.27
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Mustang Bio::Mustang Bio reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.27.  Full Article

Fortress Bio to sell majority stake in brokerage National Holdings

Fortress Biotech Inc said on Monday it will sell its majority stake in the independent wealth management firm National Holdings Corp , bringing an end to an unusual ownership arrangement that had drawn scrutiny from the investing and securities industries.